Exelixis Stock Price (NASDAQ:EXEL)

Add to My Stocks
$20.31 $0.17 (0.83%) EXEL stock closing price Mar 23, 2017 (Closing)
23 MAR 2017
amigobulls logo
EXEL hand_up
EXEL vs S&P 500
Closing Price: Mar 23, 2017
$20.31 ( -0.83%)
S&P 500
2346 ( -0.11%)
52 Week Price Range
1 Year Return: 415.87%
Q4 Growth*
Profitable ?
net image
2016 Q4 Net Loss
home image
☆ ☆ ☆ ☆ ☆★ ★ ★ ★ ★
Double Tap To Exit Full Screen

Exelixis Snapshot Video

17 5 2

EXEL Stock Details

Prev Close* : $20.48
Market Cap:
Day Low: $20.29
52 Week Low: $3.64
Open: $20.55
Volume: 2923268
Day High: $20.85
52 Week High: $23.49

Latest Stock Market News

Latest Articles

Exelixis News - From Partners

EXEL Stockcharts

View EXEL PE ratio, PS ratio stocks charts and compare with peers.
EXEL Chart
Note: Compare Exelixis stock price history with the index and industry peers.

Exelixis Valuation

PS ratio (
price to sales ratio

Exelixis Returns

(return on equity)

Exelixis Financial Ratios

Asset Turnover
Receivables Turnover
Debt to Equity

EXEL Industry Peers

Company Price Change (%)
Intermune (ITMN)73.890 (0%)
Qiagen (QGEN)28.740.06 (0.21%)
Bristol-myers Squibb (BMY)55.770.59 (1.05%)
Merck (MRK)63.280.22 (0.35%)
Roche Holdings (RHHBY)31.730.18 (0.57%)
Sanofi (SNY)44.510.16 (0.36%)
Swedish Orphan (SWTUY)12.860 (0%)

Top Stock Gainers

show top losers
CompanyPriceChange (%)
ALBIREO PHARMA (ALBO)23.783.48 (17.14%)
Trevena (TRVN)3.590.26 (7.81%)
Fate Therapeutics (FATE)4.640.24 (5.45%)
Sangamo BioSciences (SGMO)4.20.2 (5%)
Cara Therapeutics (CARA)16.690.6 (3.73%)
Lion Biotech (LBIO)7.40.25 (3.5%)
Immunomedics (IMMU)6.630.21 (3.27%)
Top gainers from Medical-Biomed-Genetics industry
* As of Mar 23, 2017
CompanyPriceChange (%)
Ultragenyx Pharma (RARE)71.996.37 (8.13%)
Stemline Therapeutics (STML)8.50.45 (5.03%)
Puma Biotech (PBYI)40.11.45 (3.49%)
MannKind (MNKD)1.950.07 (3.47%)
Emergent Biosolutions (EBS)28.361.01 (3.44%)
Five Prime Therapeutics (FPRX)34.891.16 (3.22%)
Idera Pharma (IDRA)2.420.07 (2.81%)
Top losers from Medical-Biomed-Genetics industry
* As of Mar 23, 2017

Exelixis, Inc. Stock News - Partner Headlines

Exelixis Financial Statements

income statement20152014201320122011
Net Sales Or Revenues37.17M25.11M31.33M47.45M289.63M
Net Income-169.73M-268.54M-244.76M-147.64M75.69M
Total Operating Expense154.69M247.52M230.94M169.87M200.09M
view Exelixis, Inc. income statement
balance sheet20152014201320122011
Total Assets332.34M327.96M503.28M721.09M393.26M
Total Liabilities436.64M442.78M437.04M424.66M302.63M
Shareholders Equity-104.3M-114.82M66.23M296.43M90.63M
view Exelixis, Inc. balance sheet
cash flow statement20152014201320122011
Net Increase (Decrease) In Assets Liabilities-25.84M-10.27M-2.26M-8.63M-264.88M
Net Cash From (Used By) Operating Activities-141.58M-235.4M-198.77M-123.14M-159.23M
Increase (Decrease) In Prop Plant And Equipment0.89M-0.08M-2.02M-0.77M0.53M
view Exelixis, Inc. cashflow statement

Exelixis Stock Message Board

Exelixis stock lost 0.2 %, and the last close price as of 22 Mar, 2017 is 20.48 for EXEL stock. Looking at Exelixis market capitalization, which currently stands at 5.95B, we can say that EXEL stock is a Mid cap stock. A value investor must look at the fundamentals of a stock, and perform Exelixis valuation, even though in the short-term sentiment and current breaking news might affect Exelixis stock price.

The terms stocks and shares mean the same thing. For Ex: Exelixis stock price and Exelixis share price mean the same thing. The volume of shares traded stood at 4701329 on the last trading day, as is evident from Exelixis stock chart, and EXEL stock quote data. A dividend is a cash payment from a company's earnings and is distributed among shareholders. Exelixis does not pay dividends. Exelixis stock price history, gives the entire historical data for EXEL stock.